Insurance; Prior Authorizations
SB 133 updates Alaska insurance law to regulate how health care insurers handle prior authorization for medical care and prescription drugs. The bill requires insurers to use a designated prior authorization process that is reasonable, efficient, and designed to reduce administrative burden on providers and facilities. It sets response deadlines for standard and expedited requests, requires confirmation of receipt, and provides that a request is deemed approved if the insurer misses the required deadline without issuing a denial, approval, or request for more information.
The bill also requires insurers to publish their prior authorization standards online in clear language, base those standards on peer-reviewed, evidence-based clinical criteria, and keep them updated. It creates a process for clinical peer review of adverse decisions, requires disclosure of reviewer qualifications, and limits how long prior authorizations remain valid, including special protections for chronic conditions. In addition, it mandates a prior authorization application programming interface aligned with federal interoperability standards so providers can check requirements and exchange requests electronically, and it expands reporting and enforcement authority for the Division of Insurance.
SB 133 further addresses step therapy. It prohibits step therapy for certain drugs used to treat Stage 4 advanced metastatic cancer when the drug is FDA-approved and supported by specified evidence or compendia. For other conditions, it requires a clear exception process and directs insurers to grant exceptions when a patient has already failed the required drugs under prior coverage or when the provider says the drug is necessary to save the patient’s life. The bill also clarifies that generic substitution rules are still allowed and that providers may prescribe medically appropriate drugs.
The bill’s impact on state law is substantial: it adds a new statutory article in Title 21 governing prior authorization practices, defines key terms, imposes reporting duties on insurers, authorizes regulatory enforcement and civil penalties, and sets an effective date of January 1, 2027 for most provisions. It also amends existing law on religious nonmedical providers without changing the basic scope of that section. Insurers, utilization review organizations, health care providers, and covered persons will all be affected by the new timelines, transparency requirements, electronic standards, and appeal-related obligations.
The overall sentiment appears strongly favorable. The bill passed the Senate unanimously and the House overwhelmingly, including a 40-0 final passage vote, suggesting broad bipartisan support for reducing delays and increasing transparency in insurance utilization review. The main points of contention, to the extent reflected in the text, are the administrative and compliance burdens placed on insurers and utilization review organizations, the strict approval-by-default deadlines, and the limits on step therapy, especially for cancer treatment and for patients who have already failed prior therapies. Supporters appear to have prioritized patient access, provider efficiency, and clearer insurer accountability.
SB 133 creates a new set of insurance regulations in AS 21.07 governing prior authorization, electronic prior authorization interfaces, peer review, validity periods, adverse determination notices, step therapy exceptions, annual reporting, and enforcement. It requires insurers to publish standards, meet response deadlines, and comply with evidence-based criteria, while giving the Division of Insurance authority to examine compliance and impose penalties up to $25,000 per instance. The bill also defines terms such as chronic condition, expedited request, standard request, prior authorization, step therapy protocol, and utilization review organization, and it takes effect January 1, 2027, with immediate authority for implementing regulations.
The bill appears to have been viewed positively overall, with no recorded opposition in the Senate final passage vote and unanimous House final passage. The voting history suggests broad support for reforms that speed up prior authorization decisions, improve transparency, and limit step therapy barriers. The absence of committee transcript material limits insight into detailed debate, but the strong votes indicate the measure was not highly controversial at the floor level.
The likely areas of contention are the bill’s operational demands on insurers and utilization review organizations, including short turnaround times, automatic approval if deadlines are missed, mandatory publication of detailed standards, and new reporting and enforcement requirements. Another notable issue is the restriction on step therapy, especially the categorical protection for certain Stage 4 advanced metastatic cancer treatments and the requirement to honor prior failures under other plans. These provisions favor patients and providers seeking faster access to care, while insurers may view them as limiting utilization management and increasing costs and administrative complexity.